Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB1 | P11230 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770146 | 0.92 | CHRNA3 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL428188 | 0.75 | CHRNB2 (0.56) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL24467086 | 0.74 | NOS1 (0.45) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29697723 | 0.71 | CHRNB4 (0.63) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7373184 | 0.71 | CHRNB2 (0.64) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL8441392 | 0.70 | CHRNB1 (0.63) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL24760047 | 0.70 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3322615 | 0.70 | CHRNB2 (0.60) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3322622 | 0.70 | CHRNB2 (0.60) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL8436708 | 0.70 | CHRNB4 (0.65) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | IRAK1, IRAK2, IRAK4 | CHRNB1 3922/4885CHRNB2 4774/4885CHRNB4 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.